Zhitong Finance App News, Weilizhibo-B (09887) announced that the full abstracts of the six studies (covering clinical research, translational research and meta-analysis) of the self-developed Velisign ^® (opatisumimab, anti-PD-L1/4-1BB bispecific antibody) and LBL-034 (GPRC5D/CD3 bispecific T-cell connector, TCE) were published on the official website of the 2026 European Society of Medical Oncology (ESMO 2026). This data collection shows trends in long-lasting relief and prolonged survival benefits of Velisign ^® in multiple immune “cold tumors”, supports its potential as a pan-tumor therapy, and highlights the differentiation capabilities of the company's X-body and TCE technology platforms. Notably, three studies, Verisign ^{® and LBL-034, were selected for ESMO's preferred oral presentation in 2026, and one study} was selected as the Breakthrough Summary (LBA). Detailed and updated data on these studies will be released during ESMO's oral report in 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.